SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

OPK RSS Feed
Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/19/2017 7:32:54 AM - Followers: 163 - Board type: Free - Posts Today: 2

Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
SureTrader
Interactive Brokers Advertisement
OPK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OPK News: Current Report Filing (8-k) 10/12/2017 08:16:31 AM
OPK News: OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan 10/12/2017 08:00:00 AM
OPK News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/20/2017 03:55:26 PM
OPK News: Statement of Changes in Beneficial Ownership (4) 09/20/2017 06:13:26 AM
OPK News: OPKO’s BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care 09/19/2017 08:00:00 AM
PostSubject
#5667   We need all the help we can get game7alcs 10/19/17 07:32:54 AM
#5666   preferential treatment by japans gov $27 10/19/17 06:13:18 AM
#5665   Your point? game7alcs 10/18/17 03:55:35 PM
#5664   the parent of Japan Tobbacco is ....the government $27 10/18/17 04:09:35 AM
#5663   Yea I don't know anything about them. terry hallinan 10/15/17 02:36:43 AM
#5662   Yea I don't know anything about them. Hopefully game7alcs 10/12/17 10:29:53 AM
#5661   Frankly.... I like these deals... WHY?? Because the now invest 10/12/17 09:37:50 AM
#5660   Sure that JT will work to get this now invest 10/12/17 08:54:03 AM
#5659   • OPKO Health (NYSEMKT:OPK) unit EirGen Pharma inks game7alcs 10/12/17 08:38:42 AM
#5658   Same here game7alcs 10/11/17 10:07:59 PM
#5657   Or it could mean something lol You never know Juice555 10/11/17 10:06:40 PM
#5656   Yea I think it's supposed to be tv game7alcs 10/11/17 10:05:14 PM
#5655   I thought it will be TV ad... I Juice555 10/11/17 10:02:54 PM
#5654   I wonder if that is their advertising campaign game7alcs 10/11/17 09:49:25 PM
#5653   Nice to see it out there An update from Juice555 10/11/17 09:34:03 PM
#5652   This vehicle was double parked on my block mvan13 10/11/17 09:01:33 PM
#5651   Maybe there are no updates to send out? game7alcs 10/11/17 11:03:26 AM
#5650   Frost... just doesn't give out updates... Guess Common now invest 10/09/17 02:51:38 PM
#5649   Love to see this puppy close below 6.90! WovenO2 10/04/17 01:57:45 PM
#5648   I don't think it means anything but Dr. game7alcs 10/03/17 11:11:13 AM
#5647   Who's the four other people trading this? WovenO2 09/29/17 02:53:16 PM
#5646   Sell WovenO2 09/29/17 02:28:00 PM
#5645   Sep 26, 2017 Ladenburg Thalmann 2017 Healthcare Conference Presentation joe_techi 09/28/17 09:37:11 AM
#5644   A Good and Sweet Year back :) MazelTov 09/27/17 10:35:53 PM
#5643   Shana Tova Juice555 09/27/17 10:19:59 PM
#5642   $OPK Opko Health Inc https://www.barchart.com/story/stocks/quotes/OTIC/4 MazelTov 09/27/17 10:18:46 PM
#5641   Anyone have a more updated short position? acraft5 09/26/17 03:54:05 PM
#5640   Yup, I have 24k share. My average is acraft5 09/26/17 03:52:43 PM
#5639   I am jealous lol Yeah. I really believe our Juice555 09/26/17 12:04:20 PM
#5638   I have closed to 60k shares OPK , Sky10 09/26/17 11:59:59 AM
#5637   Yes. Thank you JP Morgan LOL Now let's see how Juice555 09/26/17 10:19:13 AM
#5636   Thank you J.P. Morgan! They created a nice acraft5 09/26/17 09:58:57 AM
#5635   McCain will die in 4-6 months, not one DegenerateGambler 09/23/17 12:07:27 AM
#5634   No problem. Take advantage of time decay. Picks77 09/22/17 09:34:14 PM
#5633   Nice Didn't look that far out but very nice Juice555 09/22/17 09:09:12 PM
#5632   January 2018 $8 for $2. Picks77 09/22/17 09:07:22 PM
#5631   Premium is so low What puts you selling? Juice555 09/22/17 09:04:41 PM
#5630   Been selling opk puts for some time Picks77 09/22/17 08:47:52 PM
#5629   Lol It took me about 7 years to understand Juice555 09/22/17 04:09:16 PM
#5628   Sounds like a good plan. I like your game7alcs 09/22/17 04:04:15 PM
#5627   Took me 18 years of trading to finally Juice555 09/22/17 04:02:33 PM
#5626   I hope it works out. I stay away game7alcs 09/22/17 04:00:28 PM
#5625   I am riding his tail to the bitter Juice555 09/22/17 03:59:21 PM
#5624   Yes for sure Hopefully we will be over $7 Juice555 09/22/17 03:58:48 PM
#5623   I believe he already has a plan. He game7alcs 09/22/17 03:58:45 PM
#5622   I don't know if it's a squeeze but game7alcs 09/22/17 03:56:35 PM
#5621   85 bagger is too far fetch I think our Juice555 09/22/17 03:47:39 PM
#5620   An 85 bagger from here. Mark this and joe_techi 09/22/17 03:25:35 PM
#5619   Let's get our SH*T together first and get Juice555 09/22/17 03:11:29 PM
#5618   Year 2022 , not 2020 Sky10 09/22/17 03:07:40 PM
PostSubject